「de」の検索結果
168件：6～10件目を表示
-
ry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJ...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
ry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0132) ...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
ry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJ...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
pan. MIEr for BeelineMED is capable of sharpening indistinct image files taken with various optical devices by installing image sharpening the algorithm developed by Logic and Design Co., Ltd. into el...
https://www.senju.co.jp/system/files/content_news/2025-02/ENG_20250220.pdf -
ting Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf